This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

Resources - Articles

The Comprehensive Package

It is widely recognised that the economic downturn has taken a turn for the better; this can be demonstrated across a number of industries, pharmaceutical development being one.

In the last two years, new chemical entity (NCE) approvals have risen to an extent not seen since the early 1990s. This is encouraging news for an industry that has gone through a significant period of change. In 2012, the US FDA signed off a total of 58 new drug announcements, an impressive rise on previous years. What is surprising about this figure is the increase in approvals of cold chain products, which made up almost 38% of new drug announcements.

With an influx in specialty pharmaceuticals, and orphan and oncology drugs, as well as flu-related vaccines this figure will continue to rise, and along with it the complexities of the drug product life cycle for compounds with special requirements.

Read more about this here

October 12, 2015


Expansion of High Potent Tableting and Powder Modification Capacity

Investment in new technologies at PCI’s global manufacturing Center of Excellence in Tredegar, Wales, to double highly potent tableting capacity... View Article

PCI Welcomes New Chief Financial Officer and SVP, Serge Dupuis

PCI is pleased to welcome Serge Dupuis as Senior Vice President and Chief Financial Officer. Serge’s appointment supports PCI’s continued... View Article

x